NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Novo Nordisk NVO is expected ... is approved as an Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes (T2D) and as a Wegovy injection for weight management.